GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study

Journal article

Peer reviewed

B.M Slomovitz, V.L Filiaci, R.L Coleman, J.L Walker, A.C Fleury, L.L Holman and D.S Miller

Gynecologic oncology, Vol.149, pp.2-2

2018-06

Metrics

65 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.26 Diabetes; 1.26.1418 Metformin
Web Of Science research areas: Obstetrics & Gynecology; Oncology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study
Creators: B.M Slomovitz - University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
V.L Filiaci - Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA
R.L Coleman - The University of Texas MD Anderson Cancer Center, Houston, TX, USA
J.L Walker - The University of Oklahoma, Oklahoma City, OK, USA
A.C Fleury - Women's Cancer Center of Nevada, Las Vegas, NV, USA
L.L Holman - The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
D.S Miller - The University of Texas Southwestern Medical Center, Dallas, TX, USA
Publication Details: Gynecologic oncology, Vol.149, pp.2-2
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Dept of Obstetrics & Gynecology
Language: English
Resource Type: Journal article
Record Identifier: 991031598298802976